share_log

Aditxt | 8-K/A: Current report (Amendment)

Aditxt | 8-K/A: Current report (Amendment)

Aditxt | 8-K/A:重大事件(修正)
美股SEC公告 ·  2024/11/22 05:21

Moomoo AI 已提取核心信息

Appili Therapeutics shareholders have overwhelmingly approved the proposed acquisition by Aditxt's subsidiary Adivir. The transaction deadline has been extended from November 19 to December 15, 2024, with Adivir agreeing to pay Appili a $115,000 waiver fee for the delay.Under the amended agreement, Appili shareholders will receive 0.0000686251 Aditxt shares and US$0.0467 cash for each Appili share, valuing the deal at approximately US$0.04673 per share. The transaction requires Aditxt to raise at least US$20 million in financing and repay minimum 50% of Appili's senior secured debt at closing, with remaining debt to be repaid by December 31, 2024.The company's financial position remains challenging with a $2.3 million loss for the six months ended September 30, 2024. Long-term debt totaled $10.4 million, including restructured loans from Long Zone Holdings due December 31, 2024, and bridge loans from Bloom Burton. The company continues to operate under going concern uncertainty pending transaction completion.
Appili Therapeutics shareholders have overwhelmingly approved the proposed acquisition by Aditxt's subsidiary Adivir. The transaction deadline has been extended from November 19 to December 15, 2024, with Adivir agreeing to pay Appili a $115,000 waiver fee for the delay.Under the amended agreement, Appili shareholders will receive 0.0000686251 Aditxt shares and US$0.0467 cash for each Appili share, valuing the deal at approximately US$0.04673 per share. The transaction requires Aditxt to raise at least US$20 million in financing and repay minimum 50% of Appili's senior secured debt at closing, with remaining debt to be repaid by December 31, 2024.The company's financial position remains challenging with a $2.3 million loss for the six months ended September 30, 2024. Long-term debt totaled $10.4 million, including restructured loans from Long Zone Holdings due December 31, 2024, and bridge loans from Bloom Burton. The company continues to operate under going concern uncertainty pending transaction completion.
Appili Therapeutics的股东已压倒性地批准了Aditxt子公司Adivir的收购提议。交易截止日期已从2024年11月19日延长至2024年12月15日,Adivir同意支付Appili 115,000美元的豁免费以弥补延误。根据修订后的协议,Appili股东将每股获得0.0000686251股Aditxt股票和0.0467美元现金,交易总值约为每股0.04673美元。该交易要求Aditxt至少筹集2000万美元融资,并在交易完成时偿还Appili至少50%的高级担保债务,其余债务需在2024年12月31日前偿还。公司的财务状况仍然面临挑战,截至2024年9月30日的六个月内损失达到230万美元。长期债务总额为1040万美元,包括到期日为2024年12月31日的Long Zone Holdings重组贷款和来自Bloom Burton的桥接贷款。公司在交易完成前继续在持续经营不确定性的情况下运营。
Appili Therapeutics的股东已压倒性地批准了Aditxt子公司Adivir的收购提议。交易截止日期已从2024年11月19日延长至2024年12月15日,Adivir同意支付Appili 115,000美元的豁免费以弥补延误。根据修订后的协议,Appili股东将每股获得0.0000686251股Aditxt股票和0.0467美元现金,交易总值约为每股0.04673美元。该交易要求Aditxt至少筹集2000万美元融资,并在交易完成时偿还Appili至少50%的高级担保债务,其余债务需在2024年12月31日前偿还。公司的财务状况仍然面临挑战,截至2024年9月30日的六个月内损失达到230万美元。长期债务总额为1040万美元,包括到期日为2024年12月31日的Long Zone Holdings重组贷款和来自Bloom Burton的桥接贷款。公司在交易完成前继续在持续经营不确定性的情况下运营。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息